{"id":"NCT01199705","sponsor":"CSL Behring","briefTitle":"Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)","officialTitle":"A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2011-08","completion":"2011-11","firstPosted":"2010-09-13","resultsPosted":"2013-03-20","lastUpdate":"2014-12-12"},"enrollment":25,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Deficiency"],"interventions":[{"type":"BIOLOGICAL","name":"Immune Globulin Subcutaneous (Human) (SCIG)","otherNames":["Hizentra"]}],"arms":[{"label":"IgPro20","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics of a subcutaneous immune globulin (SCIG; IgPro20) in subjects with primary immunodeficiency (PID). In addition, the study will assess the health-related quality of life and pharmacoeconomic aspects related to treatment with IgPro20.","primaryOutcome":{"measure":"IgG Trough Level","timeFrame":"During IVIG period (IV 1, IV 2, IV 3) and during SCIG period at weeks 16, 20, and 24","effectByArm":[{"arm":"IgPro20 - Per Protocol Set (PPS)","deltaMin":1.09,"sd":null},{"arm":"IgPro20 - Full Analysis Set (FAS)","deltaMin":1.11,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":10,"countries":["Japan"]},"refs":{"pmids":["25236916","24504846"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":25},"commonTop":["Local reactions","Nasopharyngitis","Upper respiratory tract infection","Influenza","Dental caries"]}}